The pipeline of hereditary angioedema is increasing on account of rising instances of angioedema, globally. Currently, an estimated prevalence of hereditary angioedema in the world is 1 in 10,000 to 1 in 150,000. Major factors driving the growth of pipeline for hereditary angioedema include increasing prevalence of attacks of angioedema and rising cases of angioedema in association with other conditions like significant hypotension resulting from abdominal attacks, low market penetration as very less number of companies are making an analog and increasing awareness of health issues. The impairment in quality of life and rising medical cost also act as the driving factor for the hereditary angioedema pipeline.
Angioedema can be defined as swelling of mucosal or skin tissues, which leads to extravasation of fluid into the interstitium and loss of vascular integrity. There are two basic types of angioedema, histaminergic angioedema and non-histaminergic angioedema. Histaminergic is basically associated with urticaria. Non-histaminergic angioedema is usually not associated with urticaria, and is only mediated by bradykinin. The non-histaminergic angioedema is further divided in four categories namely, angiotensin-converting enzyme (ACE) inhibitor-associated angioedema, hereditary angioedema (HAE), idiopathic angioedema and acquired angioedema. Hereditary angioedema is symptomatized as episodic swelling disorder and arises from autosomal dominant trait. Clinical features include nonpitting edema of external body surfaces, abdominal pain, swelling of the extremities and swelling of the mouth and throat, which can lead to asphyxiation.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of hereditary angioedema therapeutics include BioCryst Pharmaceuticals, Inc., CSL Limited, Dyax Corp., Cevec Pharmaceuticals GmbH, Global Blood Therapeutics, Inc., Isis Pharmaceuticals, Inc., iBio, Inc. Pharming Group N.V., Ra Pharmaceuticals, Inc., Shire Plc.